Gynaecologic oncology & prevention
HPV vaccination, fertility-sparing endometrial cancer treatment, and hormone-therapy risk
Last updated: October 2026 — Sources: Cochrane / EAU / ESHRE / WHO / CDC
Key takeaways
Gynaecologic oncology is not separate from fertility: primary prevention (HPV vaccination) demonstrably reduces cervical cancer, fertility-sparing treatment in early endometrial cancer is now an option for selected patients, and menopausal hormone therapy has a price to calculate. This domain separates prevention, conservative treatment and hormonal risk.
HPV vaccination at 12–13 cut cervical cancer by 87% (72–94) and CIN3 by 97% in the English registry.
Benefit falls with later age: 62% at 14–16 and 34% at 16–18 — because vaccination does not clear existing infection.
In FIGO IA endometrial cancer: pregnancy 48% and live birth 36% after conservative treatment, with possible recurrence and strict follow-up.
Daily combined hormone therapy raises breast risk in a duration-dependent way (RR 2.08 at 5–14 years).
When to evaluate?
- Abnormal uterine bleeding in a woman over 40 or with obesity/PCOS — requires endometrial assessment, not just cycle regulation.
- A young woman with grade 1 endometrial cancer who wants pregnancy — multidisciplinary discussion before any treatment.
- Strong family history of breast/ovarian cancer — genetic assessment before any hormone-therapy decision.
What not to do?
- Do not assume vaccination replaces screening — the vaccine does not cover every high-risk type.
- Do not promise a guaranteed pregnancy after conservative endometrial cancer treatment — figures are probabilistic and recurrence occurs.
- Do not use fertility-sparing studies to justify delaying treatment in high-grade or invasive tumours.
Healthcare-professional notice
This hub is independent of NPF products and does not promote them. It is informational only and does not replace individual clinical judgment. Surrogate outcomes (SDF, motility, HOMA, IIEF) are never converted into pregnancy/cure promises, and GRADE certainty is quoted as published.
Binding rule: surrogate outcomes are never converted into patient outcomes. Every certainty grade and limitation is quoted as published.
Deep dive
Cervical cancer prevention
The gap between 87% and 34% is not the vaccine but its timing: the earlier before exposure, the greater the protection. This makes school programmes more important than late catch-up campaigns.
Even with vaccination, regular screening remains necessary because bivalent/quadrivalent/nonavalent vaccines do not cover every type and do not treat prior infection.
Fertility sparing in endometrial cancer
The prerequisites: grade 1, no myometrial invasion, and a patient committed to histological surveillance. Treatment is progestin (oral or LNG-IUS) or combined with hysteroscopic resection, decided with the oncology team, not alone.
The figures: high initial complete response, then pregnancy ~48% and live birth ~36%, with expected recurrence. Patients are therefore advised to conceive early after response rather than delay.
Hormone therapy and breast risk
Risk differs by type: vaginal oestrogen alone showed no increase, oestrogen alone RR 1.33, and daily combined RR 2.08 at 5–14 years. There is therefore no absolutely 'safe' hormone therapy, only a trade-off.
Practical translation: explain the absolute increase (about two extra cases per 100 users over five years) rather than relative risks alone, and decide alongside individual risk factors.
Evidence in this domain
Each study broken into five questions: why it was run, who was studied, how it was done, the finding, and why it came out that way — then the clinical takeaway and limits, as published.
FAQ
Does HPV vaccination treat existing infection?
No. It is preventive before exposure, which is why the maximum benefit is at age 12–13 before sexual debut.
Can endometrial cancer be treated without hysterectomy?
In very selected cases (grade 1, FIGO IA, strong desire for pregnancy, commitment to follow-up) yes — but it is not a general option and needs a multidisciplinary team.
Notice: this reference is informational only and not a substitute for medical advice. Consult your doctor before making any treatment decision.